Journal article

A polymorphism in the OPRM1 3 '-untranslated region is associated with methadone efficacy in treating opioid dependence

RC Crist, GA Doyle, EC Nelson, L Degenhardt, NG Martin, GW Montgomery, AJ Saxon, W Ling, WH Berrettini

The Pharmacogenomics Journal | NATURE PUBLISHING GROUP | Published : 2018


Awarded by National Institute on Drug Abuse through the Clinical Trials Network (CTN)

Awarded by NIDA grant

Awarded by National Institute on Drug Abuse

Awarded by National Institutes of Health

Awarded by Delaware Valley Node

Funding Acknowledgements

Main START study funding came from the National Institute on Drug Abuse through the Clinical Trials Network (CTN) through a series of grants provided to each participating node: the Pacific Northwest Node (U10 DA01714), the Oregon Hawaii Node (U10 DA013036), the California/Arizona Node (U10 DA015815), the New England Node (U10 DA13038), the Delaware Valley Node (U10 DA13043), the Pacific Region Node (U10 DA13045), and the New York Node (U10 DA013046). Suboxone for the START trial was provided by Reckitt- Benckiser Pharmaceuticals (now Indivior Inc.). Dr. Berrettini was supported by the Delaware Valley Node (U10 DA13043) and by R21 DA036808. Dr. Crist was supported by NIDA grant K01 DA036751 and pilot project funding through the Veterans Integrated Service Network (VISN) 4 Mental Illness Research, Education, and Clinical Center (MIRECC). Funding support for the Comorbidity and Trauma Study (CATS) was provided by the National Institute on Drug Abuse (R01 DA17305); GWAS genotyping services at the Center for Inherited Disease Research (CIDR) at The Johns Hopkins University were supported by the National Institutes of Health (contract N01-HG-65403). We thank Elisia Clark, Emre Karatas, Alison Lai, and Wint Thu Saung for contributions to the genotyping of the START population.